 |
 |
Educational Materials
|
|
|
|
Educational MaterialsBelow you will find a number of resources relevant to Trofile™, tropism or maraviroc. Clicking on an image will begin a download of the selected document to your desktop. Publications and AbstractsPlease note that clicking on the links below will take you to a website outside of TrofileAssay.com. These links are provided only as a service and Monogram Biosciences is not responsible for the content of these sites. 2008Reeves J, Han D, Wilkin T, et al. An enhanced version of the Trofile HIV co-receptor tropism assay predicts emergence of CXCR4 use in ACTG5211 vicriviroc trial samples. Paper presented at CROI 2008; Feb. 3-6, 2008; Boston, MA. Kekitiinwa A, Kasirye P, Friedman D, et al. HIV-1 subtype and antiretroviral therapy in Uganda. Paper presented at CROI 2008; Feb. 3-6, 2008; Boston, MA. 2007Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis. 2007;44:591-595. Nelson M, Fatkenheurer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results. Paper presented at CROI 2007; February 25–28, 2007; Los Angeles, CA. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5 tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada. Paper presented at CROI 2007; February 25–28, 2007; Los Angeles, CA. Huang W, Eshleman SH, Toma J, Fransen S, Stawiski E, Paxinos EE, Whitcomb JM, Young AM, Donnell D, Mmiro F, Musoke P, Guay LA, Jackson JB, Parkin NT, Petropoulos CJ.
Related Articles, Links
Co-receptor Tropism in Subtype D HIV-1: High Prevalence of CXCR4 Tropism and Heterogeneous Composition of Viral Populations.
J Virol. 2007 May 16; [Epub ahead of print]
PMID: 17507467 Kraft Z, Derby NR, McCaffrey RA, Niec R, Blay WM, Haigwood NL, Moysi E, Saunders CJ, Wrin T, Petropoulos CJ, McElrath MJ, Stamatatos L.
Related Articles, Links
Macaques Infected with a CCR5-Tropic Simian/Human Immunodeficiency Virus (SHIV) Develop Broadly Reactive Anti-HIV Neutralizing Antibodies.
J Virol. 2007 Jun;81(12):6402-11. Epub 2007 Mar 28.
PMID: 17392364 Eshleman SH, Husnik M, Hudelson S, Donnell D, Huang Y, Huang W, Hart S, Jackson B, Coates T, Chesney M, Koblin B.
Related Articles, Links
Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection.
AIDS. 2007 May 31;21(9):1165-1174.
PMID: 17502727 Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM.
Related Articles, Links
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
Clin Infect Dis. 2007 Feb 15;44(4):591-5. Epub 2007 Jan 17.
PMID: 17243065 Masquelier B, Capdepont S, Neau D, Peuchant O, Taupin JL, Coakley E, Lie Y, Carpentier W, Dabis F, Fleury HJ; ANRS CO3 Aquitaine Cohort.
Related Articles, Links
Virological characterization of an infection with a dual-tropic, multidrug-resistant HIV-1 and further evolution on antiretroviral therapy.
AIDS. 2007 Jan 2;21(1):103-6.
PMID: 17148975 2006Coakley E, Benhamida J, Chappey C, et al. An evaluation of tropism profiles and other characteristics among 3988 individuals screened from A4001026, A4001027 (MOTIVATE 1) and A4001028 (MOTIVATE 2) studies for maraviroc. In: Second International Workshop on Targeting HIV Entry; Oct 20–21, 2006; Boston, MA. Abstract 8. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, Chappey C, Kiss LD, Paxinos EE, Petropoulos CJ.
Related Articles, Links
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism.
Antimicrob Agents Chemother. 2007 Feb;51(2):566-75. Epub 2006 Nov 20.
PMID: 17116663 Limoli K, Whitcomb J, Kiss L, et al. Technical validation defines the performance of monogram’s HIV co-receptor tropism assay. In: AIDS 2006 – XVI International AIDS Conference; August 13–18; 2006; Toronto, Canada. Abstract THPE0045. Mayer H, van der Ryst E, Saag M, et al. Safety and efficacy of maraviroc (MVC), a novel CCR5 antagonist, when used in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial. In: AIDS 2006 – XVI International AIDS Conference; August 13–18, 2006; Toronto, Canada. Abstract THLB0215. Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, Price RW, Spudich SS, Lampiris H, Hoh R, Leigler T, Martin JN, Deeks SG.
Related Articles, Links
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia.
J Infect Dis. 2006 Oct 1;194(7):926-30. Epub 2006 Aug 29.
PMID: 16960780 2005Daar ES, Lynn HS, Donfield SM, Lail A, O'Brien SJ, Huang W, Winkler CA; Hemophilia Growth and Development Study.
Related Articles, Links
Stromal cell-derived factor-1 genotype, coreceptor tropism, and HIV type 1 disease progression.
J Infect Dis. 2005 Nov 1;192(9):1597-605. Epub 2005 Sep 30.
PMID: 16206074 |
 |
|
